Largely ignored: The impact of the threshold value for a QALY on the importance of a transferability factor

European Journal of Health Economics

Volumn 12, Issue 5, 2011, Pages 397-404

  Vemer, Pepijn ^a   Rutten Van Mölken, Maureen P M H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cost effectiveness; Multinational; QALY; Smoking cessation; Threshold value; Transferability; Willingness to pay

Indexed keywords

ARTICLE; DEMOGRAPHY; HEALTH CARE COST; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION;

CHECKLIST; COST-BENEFIT ANALYSIS; EUROPE; FINANCING, PERSONAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS; SMOKING; SMOKING CESSATION;

EID: 80655124410     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0253-3     Document Type: Article

References (26)

1. Drummond, M., Barbieri, M., Cook, J., Glick, H., Lis, J., Malik, F., et al.: Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12, 409-418 (2009)
2. Boulenger, S., Nixon, J., Drummond, M.F., Ulmann, P., Rice, S., de Pouvourville, G.: Can economic evaluations be made more transferable? Eur. J. Health Econ. 6, 334-346 (2005)
3. Antonanzas, F., Rodriguez-Ibeas, R., Juarez, C., Hutter, F., Lorente, R., Pinillos, M.: Transferability indices for health economic evaluations: methods and applications. Health Econ. 18, 629-643 (2009)
4. Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10, 157-165 (2009)
5. Vemer, P., Rutten-van Mölken, M.P.M.H.: Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 13, 230-241 (2010)
6. O'Regan C, Baker C, Marchant N. The cost-effectiveness of the novel prescription therapy varenicline in Scotland. In: Meeting of the Society for Research on Nicotine and Tobacco, 14-18 Feb, Madison (WI), USA (2006)
7. Hoogendoorn, M., Welsing, P., Rutten-van Mölken, M.P.M.H.: Cost-effectiveness of varenicline compared with bupropion, NRT and nortriptyline for smoking cessation in the Netherlands. Curr. Med. Res. Op. 24, 51-61 (2008) (Pubitemid 351160238)
8. Bolin, K., Mörk, A., Willers, S., Lindgren, B.: Varenicline as compared to bupropion in smoking cessation therapy - Cost- utility results for Sweden. Respir. Med. 102, 699-710 (2008)
9. Howard, P., Knight, C., Boler, A., Baker, C.: Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 26, 497-511 (2008) (Pubitemid 351704858)
10. Hughes, J., Stead, L., Lancaster, T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. 1 Art.No. CD000031 (2007). doi:10.1002/14651858.CD000031.pub3 (Pubitemid 351820390)
11. Jorenby, D.E., Hays, J.T., Rigotti, N.A., et al.: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-released bupropion for smoking cessation: a randomized controlled trial. J. Am. Med. Assoc. 296, 56-63 (2006)
12. Rasch, A., Greiner, W.: Gesundheitsökonomisches Modell der Raucherentwöhnung mit Vareniclin. Suchtmedizin in Forschung und Praxis 11, 47-55 (2009)
13. Annemans, L., Nackaerts, K., Bartsch, P., Prignot, J., Marbaix, S.: Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin. Drug Investig. 29, 655-665 (2009)
14. Rawlins, M.D., Cuyler, A.J.: National Institute for Clinical Excellence and its value judgements. Br. Med. J. 329, 224-227 (2004) (Pubitemid 39013284)
15. Pomp, M., Brouwer, W.B.F., Rutten, F.F.H.: QALY-tijd. Nieuwe medische technologie. kosteneffectiviteit en richtlijnen. Den Haag, Centraal Planbureau (CPB) (2007)
16. RVZ. Zinnige en duurzame zorg (Sensible and sustainable Care). Zoetermeer. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care) Report nr. 06/06 (2006)
17. RVZ. Rechtvaardige en duurzame zorg (Justified and sustainable care). Den Haag. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care) Report nr. 07/04. ISBN 978-90-5732-183-2 (2007)
18. Perleth, M., Gibis, B., Gohlen, B.: A short history of health technology assessment in Germany. Int. J. Technol. Assess. Health Care. 25(Suppl 1), 112-119 (2009)
19. Cleemput, I., Van Wilder, P.: History of health technology assessment in Belgium. Int. J. Technol. Assess. Health Care. 25(Suppl 1), 82-87 (2009)
20. KCE. Drempelwaarden voor kosteneffectiviteit in de gezondheidszorg. Brussels. Federaal Kenniscentrum voor de Gezondheidszorg (KCE). Report nr. 100A (2008)
21. LFN. The Swedish pharmaceutical reimbursement system. Pharmaceutical Benefits Board (LFN), Solna (2007)
22. Mo?̈se P, Docteur E. Pharmaceutical pricing and reimbursement in Sweden. OECD health working papers no 28, OECD, Paris (2007)
23. Rochaix L. In France, no threshold value is used when making health care decision. Report nr. 29006531, personal communication, 5 Jan (2010)
24. Kroes ME, Mastenbroek CG. Stoppen-met-rokenprogramma: te verzekeren zorg! Diemen. CVZ (2009)
25. Thun, M.J., Apicella, L.F., Henley, S.J.: Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J. Am. Med. Assoc. 284, 706-712 (2000) (Pubitemid 30646339)
26. Feenstra, T.L., van Genugten, M.L., Hoogenveen, R.T., Wouters, E.F., Rutten-van Mölken, M.P.M.H.: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 164, 590-596 (2001) (Pubitemid 32801662)